Company Overview and News

9
AKRX vs. AMPH: Which Stock Should Value Investors Buy Now?

2018-09-13 zacks
Investors with an interest in Medical - Generic Drugs stocks have likely encountered both Akorn (AKRX - Free Report) and Amphastar Pharmaceuticals (AMPH - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
AMPH AKRX

 
Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference 2018

2018-08-29 globenewswire
RANCHO CUCAMONGA, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President, and Bill Peters, CFO will be presenting at the Wells Fargo Healthcare Conference on Thursday, September 6, 2018 at 9:10 a.m. Eastern Time in Boston, MA.
AMPH

9
AKRX vs. AMPH: Which Stock Should Value Investors Buy Now?

2018-08-27 zacks
Investors looking for stocks in the Medical - Generic Drugs sector might want to consider either Akorn (AKRX - Free Report) or Amphastar Pharmaceuticals (AMPH - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
AMPH AKRX

4
Amphastar (AMPH) Q2 2018 Results - Earnings Call Transcript

2018-08-11 seekingalpha
Good day, ladies and gentlemen, and welcome to the Amphastar Pharmaceuticals Second Quarter Earnings Conference Call. At this time all participants are in a listen-only mode. Later we’ll conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions].
WFC WFCNP AMPH

 
AMPH / Amphastar Pharmaceuticals, Inc. 10-Q (Quarterly Report)

2018-08-09 sec.gov
amph_Current_Folio_10Q Table of Contents
AMPH

5
Amphastar Pharmaceuticals (AMPH) Misses Q2 Earnings Estimates

2018-08-09 zacks
Amphastar Pharmaceuticals (AMPH - Free Report) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.11 per share a year ago. These figures are adjusted for non-recurring items.
AMPH VNOM COLL AKBA

 
AMPH / Amphastar Pharmaceuticals, Inc. 8-K (Current Report)

2018-08-08 sec.gov
amph_Current_Folio_8K
AMPH

 
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2018

2018-08-08 globenewswire
RANCHO CUCAMONGA, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2018.
AMPH

 
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2018

2018-08-03 globenewswire
RANCHO CUCAMONGA, Calif., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its second quarter of 2018 ended June 30, 2018, after the market closes on Wednesday, August 8, 2018, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
AMPH

1
MannKind Negotiates Debt With Deerfield - Issues Shares In Process

2018-07-13 seekingalpha
MannKind (MNKD) announced today via an 8-K SEC filing that the company has negotiated the terms of Deerfield debt again and as a result has issued 7,367,839 shares to handle some of the payment that was due on July 18th of this year. The company had $10,000,000 due and erased $7,000,000 of that obligation with this transaction. The other $3,000,000 has been deferred to August 31st of 2018. That amount can be paid with shares (at the option of Deerfield) at a price of $1.
AMPH MNKD

 
AMPH / Amphastar Pharmaceuticals, Inc. 8-K (Current Report)

2018-07-09 sec.gov
AMPH_Current_Folio_8K_NonFinancial
AMPH

 
Amphastar Announces Expansion of Amphastar Nanjing Pharmaceuticals Inc.

2018-07-09 globenewswire
RANCHO CUCAMONGA, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced business expansion plans for its subsidiary, Amphastar Nanjing Pharmaceuticals Inc. (“ANP”). To date, ANP has provided Active Pharmaceutical Ingredients (“APIs”) and starting materials specifically to Amphastar. After the expansion is completed, ANP intends to begin selling APIs both to Amphastar and externally around the world to expand its overall markets.
AMPH

76
AGN vs. AMPH: Which Stock Is the Better Value Option?

2018-07-02 zacks
Investors interested in stocks from the Medical - Generic Drugs sector have probably already heard of Allergan (AGN - Free Report) and Amphastar Pharmaceuticals (AMPH - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
AMPH AGN

178
Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges

2018-06-21 seekingalpha - 10
Anika Therapeutics (ANIK) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (‘OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combination anti-inflammatory formula that combines hyaluronic acid (‘HA) with a steroid (triamcinolone hexacetonide). HA serves as a lubricant for arthritic joints.
NTLA CYAD AMGN ANIK PSTI CRSP SRPT MDWD CANF AMPH NVUS RSLS ALXN ALNA KALA CYAD CLBS PRTA PSTIW

9
Amphastar Announces Approval for Isoproterenol Hydrochloride Injection, USP

2018-06-19 globenewswire
RANCHO CUCAMONGA, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has granted approval of its abbreviated new drug application (“ANDA”) for Isoproterenol Hydrochloride Injection, USP 0.2mg/mL, 1mL and 0.2mg/mL, 5mL single dose vial. Isoproterenol Hydrochloride is indicated for multiple uses including for mild or transient episodes of heart block that do not require electric shock or pacemaker therapy.
AMPH VRX

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to AMPH / Amphastar Pharmaceuticals, Inc. on message board site Silicon Investor.

A Camphouse cupboard - My Notes to me A Camphouse cupboard - My Notes to me A Camphouse cupboard - My Notes to me APH: Amphenol Corporation APH: Amphenol Corporation APH: Amphenol Corporation
CFV - Camphor Ventures CFV - Camphor Ventures CFV - Camphor Ventures Amphenol (APH) Turnaround or Takeover? Amphenol (APH) Turnaround or Takeover? Amphenol (APH) Turnaround or Takeover?
CUSIP: 03209R103